An overview of the diagnosis and management of MDS, including recent treatment, was discussed in a paper published in the American Journal of Hematology.
As myeloproliferative neoplasms (MPNs) are a rare form of blood cancer, patients may not be aware of its effects. How do MPNs affect a patient’s quality of life, and what do your patients need to know?
Researchers seek to identify biomarkers that may be predictive of erythroid response in patients with lower-risk myelodysplastic syndromes without a chromosome 5q deletion.
Researchers sought to determine whether differences in treatment guidelines for MDS would account for nonadherence to expert guidance.
Researchers sought to identify inflammation-related genes that may be associated with leukemic transformation in patients with MDS with myelofibrosis.
Researchers sought to review the EU’s marketing authorization for luspatercept to treat select patients with MDS or transfusion-dependent beta thalassemia.
Researchers sought to determine whether
IRF4 expression is associated with an increased susceptibility to de novo AML and myelodysplastic syndrome.
Researchers found a high incidence of thromboembolic events in young patients with myeloproliferative neoplasms, especially polycythemia vera.
Researchers sought to determine whether pevonedistat plus azacitidine would result in a lower residual mutation load than seen with azacitidine alone in patients with MDS.
Researchers sought to determine whether there is a link between exposure to a soluble CD40 ligand (sCD40L) and expression of TNFα in bone marrow mononuclear cells from patients with MDS.
Researchers sought to determine what is the best method for detecting liver iron abundance in patients with MDS.
Researchers sought to determine whether an HSP90 inhibitor and a plant-derived coumarin would have antitumor effects in patients with MDS.
Researchers sought to determine what factors may help predict what patients with MDS or AML would respond to treatment with azacitidine.
Researchers evaluated the rates and significance of HFE variants in a population of patients with MDS.
Researchers sought to determine whether paroxysmal nocturnal hemoglobinuria clones might predict treatment responses for patients with MDS and aplastic anemia.
Researchers assessed if older patients with high-risk myelodysplastic syndrome experience significant overall survival benefit from hematopoietic transplantation.
A new study evaluated the prognostic value of the Fibrinogen-Albumin Ratio Index in certain conditions.
A team of researchers sought to determine whether morphologic dysplasia may serve as a biomarker of risk for transition to myelodysplastic syndrome in patients with clonal cytopenia of undetermined significance.
Observational, retrospective study revealed factors that may be linked to higher mortality risk in patients with MPN and COVID-19.
A team of investigators sought to evaluate outcomes following combination treatment with eprenetapopt and azacitadine in TP53-mutant myelodysplastic syndromes, as well as in oligoblastic acute myeloid leukemia.
A phase 3 trial suggests higher responses when epoetin alfa is added to lenalidomide in treatment of erythropoietin-refractory myelodysplastic syndromes.
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Among patients with myelodysplastic syndrome, long noncoding RNA
KIAA0125 may predict poorer overall survival and leukemia-free survival.
Researchers reviewed the challenges and future developments in ICI combination therapies for the treatment of patients with acute myeloid leukemia and myelodysplastic syndromes.
Although other flow cytometry–based prognostic scores have been proposed in the setting of MDS, their complexity has limited their clinical use.
There may be no relapse-free survival or overall survival benefits with posttransplant azaciditine in patients with high-risk AML or MDS.
Among some patients with myelodysplastic syndrome, gene expression signatures appear to be predictive of response and primary resistance to azacitidine.
With the exception of alloSCT and iron chelation therapy, many guideline treatments may not improve survival among patients with myelodysplastic syndrome.
Researchers studied survival in reduced-intensity conditioning HSCT vs non-HSCT approaches for older, transplantation-eligible patients with advanced MDS.
The first-in-class imetelstat demonstrated clinically meaningful red blood cell transfusion independence rates in lower-risk MDS, according to results of a phase 2 trial.
A graft-vs-MDS effect of graft-vs-host disease has been observed for some patients with acute leukemia post-HSCT, but has been less well studied in those with MDS.
Researchers aimed to determine iron and oxidative stress characteristics and their effects on survival in patients with lower-risk myelodysplastic syndrome.
A study with murine models suggests that quercetin may induce autophagy in myelodysplastic bone marrow among patients with myelodysplastic syndrome.
For patients with myelodysplastic syndrome, 5-azacitidine treatment delays showed some links to outcomes, while dose reductions had less impact.
As transplantation-related complications are high among patients with MDS, determining which patients will benefit from HSCT is essential.
Premyelodysplastic syndrome blood kinetics are linked to both disease risk and overall survival.
The administration of cedazuridine with decitabine prevents the degradation of decitabine by CDA in the gastrointestinal tract and liver increasing its systemic exposure.
Novel treatment options are needed to improve outcomes for patients with
TP53-mutated myeloid neoplasms.
Immunomodulator indoleamine-2,3-dioxygenase may be a promising predictor and therapeutic target for patients with higher-risk myelodysplastic syndromes.
Given the prevalence, the IWG-PM evaluated available evidence to determine whether
SF3B1-mutated MDS should be recognized as a distinct disease subtype.
Transfusion independence for at least 8 weeks was observed in 38% of patients receiving luspatercept compared with 13% of patients receiving placebo.
Rates of nonrelapse mortality and 3-year overall survival were similar between patients 55 to 64 years old and patients 65 years or older who underwent transplantation.
Researchers conducted a meta-analysis to determine whether iron chelation therapy leads to improved overall and leukemia-free survival in patients with myelodysplastic syndrome.
Transfusion dependence, very high-risk cytogenetics, and high serum ferritin were identified as risk factors for death in a multivariable analysis.
Researchers identified 8 combinations of genes that could be used to predict whether a patient will respond to treatment with hypomethylating agents.
Nonmyeloablative conditioning was associated with increased nonrelapse mortality and shorter overall survival compared with reduced-intensity conditioning.
Myelodysplastic syndromes display a high degree of heterogeneity, making it difficult to establish a standard of care for patients.
Patients who received androgen therapy demonstrated improvements in erythroid, platelet, and neutrophil measures.
The rate of 5-year overall survival in patients with myelodysplastic syndrome who underwent second allogeneic hematopoietic stem cell transplantation was 25.3%.
A variety of immune pathways mediate the pathogenesis of myelodysplastic syndromes, suggesting that the immune system may be a feasible therapeutic target.
Compared with hypomethylating agents, intensive chemotherapy was associated with higher overall response and complete remission rates.